ArticleOral health & preventive dentistry2026
The Feasibility of Exosome-Enriched Platelet-rich Fibrin (PRF) for the Treatment of Gingival Recessions: A Case Series of 27 Patients.
Article in Oral health & preventive dentistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treatment of Severe Periodontitis using Exosome-Mediated Combination Therapies: A Retrospective Cohort Study.Oral health & preventive dentistry · 2026Article
- Extracellular Vesicles as Orchestrators of Osteoimmunomodulation in Peri-Implantitis: Implications for Bone Regeneration.Clinical implant dentistry and related research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGiven the emerging potential of bioactive, cell-free regenerative therapies, integrating exosomes into dental practice may provide a biologically driven, minimally invasive method to improve soft tissue healing and root coverage outcomes. Hence, this first case series aimed to clinically assess the efficacy and safety of exosome-enriched solid platelet-rich fibrin (Exos-solid-PRF) to treat gingival recessions. MATERIALS AND
methodsTwenty-seven patients (125 teeth) treated between January 2023 and July 2024 using a minimally invasive vestibular access technique with Exos-solid-PRF and liquid-PRF were included. Autologous PRF was prepared via horizontal centrifugation and hydrated with exosomes before surgical application. Clinical parameters, such as attachment gain (AG), keratinized tissue (KT), recession depth (RD), and recession width (RW), were measured at baseline and at a 6-month follow-up.
resultsAccording to the Cairo classification system for recession, out of 125 teeth, 23 (18.4%) were recession type 1 (RT1) and 102 (81.6%) were RT2. Statistically significant improvements were observed in AG (+0.46 ± 0.84mm), RD (-1.93 ± 1.05 mm), and RW (-1.43 ± 1.43mm), with a mean root coverage of 68% and complete root coverage in 34 teeth. RT1 cases demonstrated 86% coverage, and RT2 cases achieved 64%, exhibiting the regenerative potential of this novel therapy in treating both isolated and multiple adjacent gingival recessions, particularly in the esthetic zone.
conclusionsWhile the outcomes for RT1 defects are comparable to those of gold-standard CTG approaches, the modest improvements in RT2 defects reflect both the potential and the limitations of this novel method. Additional controlled studies, long-term follow-up, and mechanistic investigations are required to validate these outcomes and optimize the therapeutic application of exosomes in clinical periodontology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.